{
  "docId": "019de070-699f-77f8-bbbb-b770da56fde3",
  "docSlug": "068a25e0403b2abb3acbdc102f073cd6",
  "documentTitle": "BioNTech | Results Presentation Deck | 25 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 25,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "other",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide illustrates the biological mechanism of a bispecific antibody targeting PD-L1 and 4-1BB.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/14",
  "deckHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3",
  "deckJsonHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json",
  "deckAnchorHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.205
      },
      "kind": "image",
      "text": "Mechanism of action diagram showing molecular interaction and cellular activity in lymph nodes and tumor microenvironment.",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9842d13-4799-4e23-a240-34fca3cdbde1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "First-in-class, next generation checkpoint immunotherapy designed to enhance T cell and NK cell function through conditional 4-1BB co-stimulation while simultaneously blocking T cell axis. Enhances proliferation and cytokine production of activated T cells, activates immune cells in tumor-draining lymph nodes, and induces tumor regression in vivo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18fc4552-b915-4bca-a8df-e8566d7376b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT311: Next-generation bispecific antibody PD-L1x4-1BB",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6836b2ac-d680-49ca-a301-2cc266f3b95f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}